<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897299</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000456426</org_study_id>
    <secondary_id>ECOG-E21971CSC</secondary_id>
    <secondary_id>NCI-7613</secondary_id>
    <secondary_id>SANOFI-AVENTIS-ECOG-E21971CSC</secondary_id>
    <secondary_id>GENOMIC-ECOG-E21971CSC</secondary_id>
    <nct_id>NCT00897299</nct_id>
  </id_info>
  <brief_title>Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy</brief_title>
  <official_title>Identifying Genomic Predictors of Recurrence After Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may&#xD;
      help doctors learn more about changes that occur in DNA and identify biomarkers related to&#xD;
      cancer. It may also help doctors predict whether cancer will come back after treatment.&#xD;
&#xD;
      PURPOSE: This laboratory study is identifying genes that may help predict recurrence in women&#xD;
      with breast cancer treated with chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the prognostic utility of the Oncotype DXâ„¢ 21 gene profile for risk of relapse in&#xD;
           women with node positive or high-risk node negative breast cancer.&#xD;
&#xD;
        -  Identify individual genes whose RNA expression is associated with an increased risk of&#xD;
           relapse in these patients.&#xD;
&#xD;
        -  Perform an exploratory analysis of individual genes whose RNA expression is associated&#xD;
           with an increased risk of relapse differentially in patients previously treated with&#xD;
           docetaxel.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Tissue samples are examined for association of RNA expression and clinical factors (e.g.,&#xD;
      tumor size, nodal status, hormone receptor status, age, menopause status), as well as&#xD;
      estrogen receptor, progesterone receptor, and HER-2/neu expression by immunohistochemistry&#xD;
      and other studies.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2005</start_date>
  <completion_date type="Actual">October 8, 2005</completion_date>
  <primary_completion_date type="Actual">October 8, 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Distant, local/regional, and ipsilateral breast relapse</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>First breast cancer recurrence</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse-free interval</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant involvement at time of first recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Estrogen Receptor</condition>
  <condition>Her-2</condition>
  <condition>Pgr</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of breast cancer&#xD;
&#xD;
               -  Node positive OR high-risk node negative disease&#xD;
&#xD;
               -  Tumor &gt; 1.0 cm in diameter&#xD;
&#xD;
          -  No locally advanced, inflammatory, or metastatic breast cancer&#xD;
&#xD;
          -  Previously treated with 4 courses of anthracycline-containing chemotherapy (i.e.,&#xD;
             doxorubicin and docetaxel OR doxorubicin and cyclophosphamide)&#xD;
&#xD;
          -  Enrolled on clinical trial ECOG-E2197&#xD;
&#xD;
          -  Adequate tumor material available in ECOG Pathology Coordination Center&#xD;
&#xD;
          -  Previously consented to future cancer-related research&#xD;
&#xD;
          -  Hormone receptor status known&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A. Sparano, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lori J. Goldstein, MD</last_name>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <results_reference>
    <citation>Badve SS, Baehner FL, Gray R, et al.: ER and PR assessment in ECOG 2197: comparison of locally determined IHC with centrally determined IHC and quantitative RT-PCR. [Abstract] American Society of Clinical Oncology 2007 Breast Cancer Symposium, 7-8 September 2007, San Francisco, California A-87, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Sparano JA, Goldstein L, Childs B, et al.: Association of individual genes with risk of relapse in operable breast cancer: analysis of E2197. [Abstract] American Society of Clinical Oncology 2007 Breast Cancer Symposium, 7-8 September 2007, San Francisco, California A-27, 2007.</citation>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <keyword>estrogen receptor</keyword>
  <keyword>HER-2</keyword>
  <keyword>PgR</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

